Unfractionated peripheral blood stem cell autografts and CD34+-enriched autografts have similar long-term culture initiating capacity in multiple myeloma
Autor: | Ali G. Turhan, S. Novault, F. Beaujean, C Bayle, J. H. Bourhis, Marie-Laure Bonnet, Jose-Luis Pico, A. L. Bennaceur, William Vainchenker |
---|---|
Rok vydání: | 1999 |
Předmět: |
Adult
Male medicine.medical_specialty Pathology Cell Cell Culture Techniques CD34 Antigens CD34 Transplantation Autologous Dexamethasone Andrology Behavior Therapy Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Distribution (pharmacology) Multiple myeloma Hematology Hematopoietic cell business.industry Hematopoietic Stem Cell Transplantation Middle Aged Hematopoietic Stem Cells medicine.disease Hematopoietic Stem Cell Mobilization Clone Cells Cytapheresis Haematopoiesis medicine.anatomical_structure Doxorubicin Vincristine Female Stem cell Multiple Myeloma business Cell Division |
Zdroj: | Hematology and Cell Therapy. 41:197-204 |
ISSN: | 1279-8509 1269-3286 |
DOI: | 10.1007/s00282-999-0197-1 |
Popis: | CD34+-enriched peripheral blood stem cells (PBSC) are increasingly being used as an autograft in patients with multiple myeloma (MM). The rationale for the use of the CD34+-enriched fraction in MM is the ability to obtain a graft with a significant reduction of contamination by plasma cells. However, the effect of such a manipulation on the proliferating potential of the engrafted cells is not known. We wished to study, as part of a randomized trial comparing the outcome in MM patients transplanted with either CD34+- enriched cells or unfractionated PBSC, the primitive hematopoietic cell content of the autografts using long-term culture initiating cell (LTC-IC) assays in 7 MM patients. In 3 patients CD34+cell-enriched fraction was compared to unfractionated PBSC whereas in the remaining 4 patients the LTC-IC assay was performed on total PBSC. The mean percentage of CD34+ cells of the CD34+ selected fraction in three patients was 82% (range 71%-96%) whereas the same percentage in PBSC varied from 0.6% to 10% in 4 patients (mean: 4.2%). Out of three patients transplanted with CD34+ cell fraction, two patients were found to have a very similar LTC-IC generating potential in their CD34+ versus PBSC fractions as this was assessed by the clonogenic cell output at week+5 per 104 CD34+ cells initiating the culture (PBSC: 92 and 168 and CD34+ fraction: 102 and 161, respectively) whereas one patient had a slightly different values (PBSC: 51 and CD34+ fraction: 103). When the PBSC fraction was compared in all 7 patients, the LTC-IC generation potential was very heterogenous, varying from 1.4 to 168. To determine if the selection procedure influences the numbers of LTC-IC’s in both fractions, we have performed limiting dilution assays to determine both the frequency of distribution of hematopoietic colonies and the frequency of LTC-IC’s in two patients. The frequency of distribution of hematopoietic colonies was linear in both CD34+ and PBSC fractions as was the frequency of LTC-IC when the corrections were made with regard to the CD34+ cell-content of the cultures (1/20). Our results indicate that the CD34+ selection procedure used in all three patients (Ceprate) is not deleterious for the generation of LTC-IC’s and these findings support the rationale for the use of this procedure in multiple myeloma for the purposes of tumor depletion. |
Databáze: | OpenAIRE |
Externí odkaz: |